We thank Koyama et al for their comments on our paper 1 and on another recently published patient series, 2 and for adding their own interesting case. Since the relapse incidence in hematopoietic stem cell transplantation (HSCT) for juvenile myelomonocytic leukemia (JMML) is around 35% in almost every recent series, 1 it is important to keep the discussion alive to continue improving the treatment of children with JMML.
First of all, in our series, intensive chemotherapy given to children with JMML before HSCT did not provide better results in terms of event-free survival, relapse incidence, and transplant-related mortality in comparison with less intensive or no chemotherapy at all. 2 That was the basis of our conclusion that in terms of toxicity and morbidity it would be better to omit intensive chemotherapy. Similarly, based on the outcome of a large multicenter EWOG-MDS/ EBMT trial Locatelli et al concluded with the same arguments that intensive chemotherapy prior to allogeneic HSCT cannot be recommended. In contrast, Koyama et al state without giving an appropriate reference, that consensus clinical opinion recommends the use of intensive AML-like chemotherapy.
Secondly, late effects after myelo-ablative conditioning are indeed of concern. However, as relapse after HSCT is the major cause of treatment failure, and in line with the EWOG-MDS/EBMT, we believe that both intensive myeloablative conditioning and a graft-versus-leukemia (GVL) effect are currently still needed to eradicate the disease. The case presented by Koyama et al is intriguing, however. The grade III acute GVHD and possible GVL effect in their patient will have played its role after this transplant using reduced intensity conditioning (RIC) and intensive pre-HSCT AML-like chemotherapy. Additional data might further support this strategy.
The ideal preparative regimen to treat JMML clearly needs to be elucidated. The future will learn whether RIC is preferable over the more toxic myeloablation, and whether reduction of leukemic load or achievement of full remission with AML-like pretreatment is needed for RIC to be successful. At this moment, we follow the EWOG-MDS/ EBMT policy of no or mild pretreatment and full myeloablation as we feel that in this rare disease entity, international collaboration is necessary to provide the final answer.
